Gemina Laboratories Ltd. (GLABF)
Gemina Laboratories Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burnaby, BC, CA. The stock last traded at $0.05, up 0.00% on the session, giving a market capitalisation of $3.8M. On trailing twelve-month figures it carries a trailing P/E of -3.03, a net margin of -13867.0%. Its beta of -0.07 implies it has historically moved less than the broad market.
Gemina Laboratories Ltd. is a Canadian biotechnology enterprise primarily focused on the investigation, creation, and commercialization of in vitro diagnostic solutions. The firm's innovation extends to developing unique surface functionalization chemistries specifically designed for the identification of pathogens and various biological markers. A significant ongoing project is the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip intended to determine active COVID-19 infections. The company maintains its corporate headquarters in Vancouver, Canada.
Gemina Laboratories Ltd. is most often compared with the following Healthcare names: